Monoclonal Antibodies

ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants

2 weeks ago talkbio0Tagged ACIP, Children Program, Enflonsia, Immunization, Infant, Merck, Monoclonal Antibodies, Respiratory syncytial virus, RSV, Vaccines

ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

2 weeks ago talkbio0Tagged Clinical Data, COVID19 (disease), immune compromise, Invivyd, long-acting protection, Monoclonal Antibodies, Pemgarda, vaccine alternatives

Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

4 weeks ago talkbio0Tagged Approved, AstraZeneca, competition, Enflonsia, Infant, Market, Merck, Monoclonal Antibodies, Respiratory syncytial virus, sanofi, United States Food and Drug Administration

Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca

Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis

5 months ago talkbio0Tagged Commission approval, Dermatitis, Atopic, European (ethnic group), Galderma, IL-31 receptor alpha, Monoclonal Antibodies, Nemluvio, nemolizumab, nodularis, Prurigo

Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody

Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

6 months ago talkbio0Tagged ANGPTL4, Cardiovascular Diseases, cholesterol, MAR001, Marea Therapeutics, Monoclonal Antibodies, Phase 2 Clinical Trials, Remnant

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

7 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings

7 months ago talkbio0Tagged Cancer Therapeutic Procedure, Genmab, GlyMab platform, Immunotherapy, licensing agreement, Monoclonal Antibodies, Scancell Holdings

Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies

Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure

7 months ago talkbio0Tagged Anti-GM-CSF, Kinevant, Monoclonal Antibodies, namilumab, Phase 2 Clinical Trials, Sarcoidosis, Pulmonary, Science

Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody

Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates

9 months ago talkbio0Tagged Abrysvo, Clesrovimab, Merck, Monoclonal Antibodies, Pfizer, Respiratory syncytial virus, RSV prevention, Vaccines

RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines

Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants

9 months ago talkbio0Tagged Clesrovimab, Clinical Trials, Co., Monoclonal Antibodies, Respiratory syncytial virus

Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.